This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Lipids and Lipid Disorders  • Nutritional and Metabolic Disorders, Other  • Alert me on articles by topic

Arch Intern Med. 1999;159:2627-2628.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE RECENT LOWERING of the fasting glucose level for the diagnosis of diabetes from 7.8 mmol/L (140 mg/dL) to 7.0 mmol/L (126 mg/dL) by the American Diabetes Association (ADA), as well as the definition of a new category—impaired fasting glucose (IFG)—defined as a fasting glucose level between 6.1 and 6.9 mmol/L (110 and 125 mg/dL) (mainly to circumvent the need to perform an oral glucose tolerance test to identify the state of impaired glucose tolerance [IGT]), draws attention to the consequences of mild elevations of the fasting plasma glucose level.¹ It is estimated that about 5.3 million previously undiagnosed individuals with diabetes as well as a large proportion of the estimated 11.6 million people with IGT in the United States may now be identifiable through the application of these new criteria using the fasting plasma glucose test. Identifying diabetes at an earlier point in its course may have significant benefit, . . . [Full Text of this Article]

RELATED ARTICLE

Reduced Coronary Events in Simvastatin-Treated Patients With Coronary Heart Disease and Diabetes or Impaired Fasting Glucose Levels: Subgroup Analyses in the Scandinavian Simvastatin Survival Study
Steven M. Haffner, Charles M. Alexander, Thomas J. Cook, Stephen J. Boccuzzi, Thomas A. Musliner, Terje R. Pedersen, John Kjekshus, Kalevi Pyörälä, and for the Scandinavian Simvastatin Survival Study Group
Arch Intern Med. 1999;159(22):2661-2667.
ABSTRACT | FULL TEXT